



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/813,383	03/20/2001	Kenneth G. Warren	098810/027 8741	3488

7590

10/01/2002

Intellectual Property Group
Pillsbury Winthrop LLP
50 Fremont Street
San Francisco, CA 94105-2228

EXAMINER

SNEDDEN, SHERIDAN

ART UNIT

PAPER NUMBER

1653

DATE MAILED: 10/01/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/813,383

Examiner

Sheridan K Snedden

Applicant(s)

WARREN ET AL.

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) claims 1-21 are canceled; claims 22-55 is/are pending in the application.
- 4a) Of the above claim(s) 48-55 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 22-47 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 20 March 2001 is/are: a) ☐ accepted or b) ☒ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☒ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.

- 4) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: ____.

DETAILED ACTION

1. Applicant's election of invention I, claims 22-47 is acknowledged. Claim 48-55 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 8. Claims 22-47 are under consideration.

Drawings

2. The drawings are objected to for the reasons indicated on the accompanying form PTO 948. Corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance. See 37 CFR 1.85(a) and MPEP 608.02(b).

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground

provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 22-47 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 5,817,629. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the instant application are within the scope of the claims 1-9 of U.S. Patent No. 5,817,629. Claim 2 of 5,817,629 is directed to a method treating multiple sclerosis (MS) by administration of amino acid residues 84-93 of myelin basic protein (MBP). The recitation of a MS by administration of peptide of at least 8 amino acid contained within the sequences of 61-106 of myelin basic protein (MBP) in claim 22 of the instant application is obvious and within the scope of the patented claim. Additionally, claim 2 of 5,817,629 anticipates claims 23-28 of the instant application as amino acids 84-93 of MBP address the limitation of each of these claims. As claim 1 of 5,817,629 recites that the R1 group may be a peptide, this claim anticipates the claims 29 of the instant application. Claim 1 of 5,817,629 specially recites an admixture with a pharmaceutical carrier and thus anticipates claim 30. Claim 8 recites the method of administration intravenously as a single or sequential dose and thus anticipates claims 31 and 32 of the instant application. Claim 1 of 5,817,629 recites the method of treating

MS which from the teachings of the patent would include chronic progressive MS or MS relapse as recited in claims 33-34 of the instant application.

With respect to claims 35-47 of the instant application, these claims recite a method of reducing free anti-MBP in a patient, but are otherwise identical to claims 22-34 of the instant application. As these claims are merely directed toward the mechanism of action in which the peptides act to treat MS; the mechanism is inherent to the treatment process. Thus, it is deemed that claims 35-47 are unpatentable over claims 1-9 of 5,817,629 for the reasons stated above.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 22-47 rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicant is also referred to the Guidelines on Written Description published at FR 66(4) 1099-1111 (January 5, 2001) (also available at www.uspto.gov). The following passage is particularly relevant.

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant identifying characteristics, i.e. structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between structure and function structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within a genus, one must describe a sufficient number of species to reflect the variation within the genus. What constitutes

Art Unit: 1653

a "representative number" is an inverse function of the skill and knowledge in the art. Satisfactory disclosure of a "representative number" depends on whether one of skill in the art would recognize that applicant was in possession of the necessary common attributes or features of the elements possessed by the members of the genus in view of the species disclosed. In an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus.

Claims 22-47 are directed to additions, deletions and substitution of a peptide having the sequence contained in SEQ ID NO: 1. With the exception of the peptides of having a sequence contained in the sequence of SEQ ID NO: 1, the skilled artisan cannot envision the detailed chemical structure of the encompassed polypeptides that would result from additions, deletions and /or substitutions. What amino acids are added, deleted and/or substituted?

Therefore, only isolated peptides comprising a sequence contained within the sequence of SEQ ID NO: 1, but not the full breadth of the claim, meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 22-47 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 22 is indefinite because of a mis-numbering of the amino acids of SEQ ID NO: 1. SEQ ID NO: 1 contains 46 amino acids and, therefore "amino acids residues 61-106" as recited in the claim are indefinite. This appears to be a mistake as page 12 of the specification list SEQ

Art Unit: 1653

ID NO: 1 in which the amino acids are numbered 61-106. However, the claim is indefinite because the Sequence Listing numbers the amino acid residues 1-46. See also the numbering of fragments in claims 23-29 and 35-42.

Claims 22-29 and 35-42 are indefinite for because the metes and bounds of "of about 8 to about 25" is unclear, e.g. is a length of 6 or 30 amino acid residues about 8 or 25.

Claims 30-34 and 43-47 are indefinite for dependency on indefinite claim 22.

Claim Rejections - 35 USC § 103

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 22-47 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hafler *et al.* (US Patent No 5,571,500) in view of Martin *et al.* (J Immunol. 1990 Jul 15;145(2):540-8) or Ota *et al.* (Nature. 1990 Jul 12;346(6280):183-7).

Hafler *et al.* teach the method of administration of autoantigens for the treatment of autoimmune diseases. Specifically, Hafler *et al.* teach the administration of MBP or fragments thereof for the treatment of MS (see column 6, line 60; claims 1, 3, 6, and 12), and specifically those fragments that are autoimmune responsive (see claim 1; regarding claims 22-29 and 35-42). Hafler *et al.* references teachings in which autoimmune diseases, such as MS, are treated by intravenous injection of MBP (column 2, line 18; regarding claims 31 and 44 of the instant application). Hafler *et al.* teaches the pharmaceutical preparation containing a mixture of

autoimmune suppressive agents (regarding claims 30 and 43 of the instant application). It is inherent that administration of the pharmaceutical would follow a protocol calling for single or sequential dosing (regarding claims 32 and 45 of the instant application). Treatment of MS, as taught by Hafler *et al.*, would contain the treatment of a patient with chronic progressive MS and a patient who has had an acute MS relapse (regarding claims 33-34 and 46-47 of the instant application). Claims 35-47 of the instant application as these claims recite a method of reducing free anti-MBP in a patient, but are otherwise identical to claims 22-34 of the instant application. As these claims are merely directed toward the mechanism of action in which the peptides act to treat MS, the scope of the method claims 35-47 in the instant application are taught by Hafler *et al.*.

Hafler *et al.* do not teach peptides of at least 8 to 25 amino acids contained within SEQ ID NO: 1.

Martin *et al.* teach Myelin basic protein (MBP) as a candidate antigen for the autoimmune process important for the pathogenesis of multiple sclerosis (MS). Additionally, Martin *et al.* teach the peptide sequences corresponding to 1-12, 25-35 (particularly relevant for claims 23-25, 28, 36-38, 41), 25-36, 27-35 (particularly relevant for claims 26 and 39), 30-39, 31-38, 31-39, 31-42 (particularly relevant for claims 27 and 40), 37-42, 39-46 and 27-46 of SEQ ID NO: 1 (see Table 1 of Martin *et al.*). (Note that SEQ ID NO: 1 is misnumbered in claims 22-47. Amino acid residues referred to in claims 22-47 as 61-106 have been renumbered 1-46 to correspond to the numbering of SEQ ID NO: 1 in the sequence listing.) Martin *et al.* do not teach the method of administration of the above peptides for the treatment of MS or a pharmaceutical composition containing the peptides.

Ota *et al.* teach the MBP peptides from amino acid residues corresponding to 1-22, 11-32 and 24-42 of SEQ ID NO: 1 (see figure 1) and the involvement of these peptides in MS. Ota *et al.* do not teach the method of administration of the above peptides for the treatment of MS or a pharmaceutical composition containing the peptides.

It would have been obvious to the person of ordinary skill in the art at the time the invention was made to substitute the fragments of MBP in the method of treating MS taught by Hafler *et al.* with the characterized immune reactive fragments of MBP taught by Martin *et al.* and Ota *et al.*. One of ordinary skill in the art would have been motivated to, and expected success by making such a substitution because the peptides taught by Martin *et al.* and Ota *et al.* are known to contain the immune reactivity property found in the whole MBP taught by Hafler *et al.*. Thus, the claimed invention was within the ordinary skill in the art to make and use at the time it was made and was as a whole, *prima facie* obvious.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheridan K Snedden whose telephone number is (703) 305-4843. The examiner can normally be reached on Monday - Friday, 8:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 746-3975 for regular communications and (703) 746-3975 for After Final communications.

Application/Control Number: 09/813,383

Page 9

Art Unit: 1653

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SKS

September 30, 2002

SKS

Christopher S. F. Low

CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600